ZymoGenetics was a biotechnology company that discovered and developed protein based therapeutics. Its approved product, Recothrom®, was for control of surgical bleeding. At the time of our financing in 2008, they were developing Atacicept for Lupus, an IL-21 antibody and an IL-29 antibody. Following the approval of Recothrom, the shares of Zymogenetics were under severe pressure in part due to the need to finance the launch of the product.